Topical after microneedling is a different question
Why applying a preparation to deliberately breached skin sits awkwardly between topical use and administration, and what is settled versus unsettled.
Applying a preparation to intact skin and injecting it into a person are clearly different acts with clearly different regulatory consequences. Applying a preparation to skin that has just been deliberately perforated sits between them, and it is the configuration most commonly used in practice.
We can find no authoritative UK determination addressing this specific configuration for this class of product, and we will not manufacture one. What we can say is that the practical arguments run in both directions, that the choice of framing has real consequences, and that a practitioner relying on the topical framing is relying on an argument rather than on a settled position.
The configuration in question
A device perforates the skin, creating channels through the barrier into viable tissue. Immediately afterwards, a preparation is applied to the surface. Some of it enters the channels. The stated purpose of the sequence is to get material past the barrier, as set out in can a vesicle cross the skin barrier.
Two descriptions of this are available and both are defensible in ordinary language.
It is topical use. The product is applied to a skin surface. It is not injected. No syringe delivers it into tissue. The preparation contacts the outside of the body and whatever enters does so passively.
It is administration. The barrier was deliberately removed for the purpose of getting the material in. The intended site of action is inside the body. Describing it as topical use relies on a description of the mechanics rather than of the purpose.
Why the framing matters
Cosmetics legislation applies to products intended for application to external parts of the body. Its restrictions on permitted substances, and its safety assessment requirements, are calibrated to that context, meaning contact with an intact barrier.
Medicines legislation engages where a product is presented as having properties for treating or preventing disease, or where it is administered with a view to restoring, correcting or modifying physiological function by pharmacological, immunological or metabolic means. That is the two-limbed test described in borderline products and the MHRA.
A product marketed for skin appearance, applied topically, sits comfortably in the first. The same product described as delivering signalling molecules to dermal cells to modify their behaviour is making a claim that engages the second, whatever the route.
Applying a product after microneedling is regulated as topical cosmetic use rather than as administration.
- Proposed mechanism
- The product is applied to the skin surface and not injected, so the topical framework applies.
- What has been shown
- We can find no authoritative UK determination addressing this configuration for this class of product. Arguments exist on both sides. The classification tests turn on presentation and function rather than on the mechanics of application, which means the claims made for a product may matter more than whether a needle delivered it.
- Highest level reached
- Not shown
- Main confounders
- Practice varies. The absence of enforcement action is not a determination. Products differ in composition and in origin, so a conclusion about one may not extend to another.
GradeNOT ASSESSABLE
What would change thisA published determination, guidance or enforcement decision addressing application to deliberately breached skin for this class of product. Until then, anyone relying on the topical framing is relying on an argument, and should know that is what they are doing.
The safety argument, which is separate
Independently of classification, there is a straightforward safety point. A product formulated for intact skin is formulated on the assumption that the barrier will keep it out of tissue. Preservative systems, microbiological limits and ingredient safety assessments are all built on that assumption.
Remove the barrier and the assumption fails. This is why we treat sterility and endotoxin as clinical parameters in this configuration, in sterility, endotoxin and cold chain. A cosmetic-grade product applied into open channels is being used outside the conditions its safety assessment covered, and that is true regardless of how the activity is classified.
| Configuration | Regulatory position | Confidence |
|---|---|---|
| Applied to intact skin, cosmetic claims | Cosmetics legislation applies | Clear |
| Applied to deliberately breached skin | Not determined for this class so far as we can establish | Unsettled |
| Injected into tissue | Administration, engaging the medicines framework on the functional limb | Clear in principle, product specific in application |
What practitioners are actually relying on
In our reading of how this is discussed in the sector, the topical framing rests on three claims: the product is not injected, it is supplied as a cosmetic or as a research material, and the practice is widespread. The first is a description of mechanics. The second is a description of how a supplier chose to label a product, which does not determine classification. The third is not a legal argument at all.
We are not asserting the framing is wrong. We are pointing out its structure, because a practitioner who believes they are standing on a settled position is in a different situation from one who knows they are standing on an argument. The second can take advice, document their reasoning and their consent process, and decide with open eyes.
Energy devices raise the same question
Fractional and ablative lasers, radiofrequency microneedling and similar devices create channels or zones of injury and are frequently paired with topical preparations for the same reason. The analysis is the same, with an additional confound: those devices deliver a thermal injury with substantial effects of its own, which makes attribution of any result even harder, as discussed in microneedling as a delivery route.
Where we leave it
Unsettled, and we are content to say so. This publication takes the view that the value of an article about regulation is a clear account of the tests, an accurate statement of what is determined, and an explicit marking of what is not. Filling the gap with a confident assertion would make the piece more quotable and less true. The primary sources are linked below and they are the authority.
Questions readers ask
Is applying a product after microneedling considered topical use?
It is commonly described that way, and we can find no authoritative UK determination addressing this configuration for this class of product. Arguments run in both directions, and the classification tests turn on presentation and function rather than on the mechanics of application.
Why does it matter whether it is topical or administration?
Because different frameworks apply, with different requirements for permitted substances, safety assessment and authorisation. The framing determines which set of rules a product and a practitioner are operating under.
Is a cosmetic-grade product safe to use after needling?
Cosmetic safety assessment assumes application to intact skin, where the barrier keeps material out of tissue. Once the barrier is deliberately breached that assumption no longer holds, which is a safety question independent of classification.
Does widespread practice make it lawful?
No. The prevalence of a practice is not a legal argument, and the absence of enforcement action is not a determination. Those are observations about enforcement capacity rather than about classification.
What should a practitioner do?
Take advice, read the primary guidance rather than supplier summaries, document the basis on which the product is being used, and ensure the consent process reflects the actual regulatory position rather than an implied approval.